Explore IndiaCurrent IndiaTomorrow IndiaSearchReport a problem
India For Tomorrow
[google-translator]Language / भाषा
← Health library
From the IFT source library

Immunisation & Infectious Disease Control

Text from the existing IFT website. Sources and claims are still under editorial review.

Original source ↗

Topic-specific proposal from the existing IFT content

The idea to investigate

Exercise a district detect-test-alert-respond pathway for one priority syndrome, including community communication.

This is a proposed pilot, not a completed project. The responsible team, location, budget, baseline and independent review must be agreed before implementation.

Data reference table

Evidence Snapshot

Read each value with its reporting period, population and limitations. A historical national reference is not a local baseline or proof that an IFT proposal works.

1 source-linked reference record. 3 measurement records still need data and a review of their relevance.

Data references for Immunisation & Infectious Disease Control
SignalReference ValuePeriod / PopulationHow to Read ItSource Status
Full vaccination at age 12–23 months

76.4%

Historical reference

NFHS-5, 2019–21

India; children aged 12–23 months; vaccination card or mother’s recall

Coverage follows the NFHS definition of the specified childhood vaccine series, not all vaccines at all ages.

Limitations: Historical household-survey estimate. Sampling, non-response and measurement limitations apply; the India figure cannot be assigned to a district or an individual. Card availability and recall can affect ascertainment.

Ministry of Finance, Government of India; underlying NFHS data: Ministry of Health and Family Welfare

Official government release

Economic Survey 2022–23: health indicator table

Published: 2023-01-31

Publication checked: 2026-11-04

Value, period and coverage checked in publication

Timeliness and completeness of surveillance

Not established

Data required — not zero

Reporting period: Information Required

Population and geography: Information Required

Proposed measure; no observed value is established here.

Limitations: Define the measure, unit, reporting period and covered population; obtain a traceable dataset and review its suitability for this topic before using a number.

Source organisation: Information Required

Direct source URL: not yet verified

Source publication date: not established

Verification status: Data required

Vaccination coverage and equity

Not established

Data required — not zero

Reporting period: Information Required

Population and geography: Information Required

Proposed measure; no observed value is established here.

Limitations: Define the measure, unit, reporting period and covered population; obtain a traceable dataset and review its suitability for this topic before using a number.

Source organisation: Information Required

Direct source URL: not yet verified

Source publication date: not established

Verification status: Data required

Alert-to-investigation time

Not established

Data required — not zero

Reporting period: Information Required

Population and geography: Information Required

Proposed measure; no observed value is established here.

Limitations: Define the measure, unit, reporting period and covered population; obtain a traceable dataset and review its suitability for this topic before using a number.

Source organisation: Information Required

Direct source URL: not yet verified

Source publication date: not established

Verification status: Data required

Different surveys, administrative records, estimates and reporting years are not interchangeable. No combined IFT score is calculated from these rows.

Section 01

Where the problem happens

Describe the patient or population failure precisely.

Delayed signals, incomplete testing and uneven vaccination can allow preventable transmission before action begins.

Detect outbreaks early and protect people through vaccination and rapid response. This topic requires evidence of actual access, readiness, quality, safety, affordability and continuity—not only a scheme, facility or installed asset.

Required context

Record state, district, city/block, village/ward or facility; date and time; population or patient group without unnecessary identity; service stage; observed harm or delay; source/method; and uncertainty. For emergencies and personal treatment, contact qualified local services rather than waiting for platform review.

Section 02

Why the problem happens

Investigate the service chain, not only the visible symptom.

Need & access

Who needs care, who reaches it and who is excluded? Test records, direct observation, staff and patient experience, and credible alternatives before calling it a verified cause.

Capacity & capability

Are the correct people, skills, rooms, equipment and supplies functional?

Flow & coordination

Where do queues, referrals, reports and handoffs fail?

Quality & safety

Are clinical, infection, medication, privacy and dignity standards met?

Finance & governance

Who owns, pays, operates, maintains, monitors and corrects failure?

Context & equity

How do geography, gender, disability, income, language and season change the pathway?

Section 03

How the parts work together

Every component needs an accountable operating definition.

Vaccination and cold chain

Define eligibility, service standard, responsible team, required inputs, handoff, safety rule, data record, escalation and follow-up.

  • Disease surveillance
  • Laboratory confirmation
  • Vector control
  • Infection prevention
  • Rapid-response teams
  • Antimicrobial resistance

Section 04

A solution suited to India

Repair the weakest handoff while protecting the whole pathway.

Verify baseline

Measure the actual local failure in immunisation & infectious disease control, including distribution and missing evidence.

Protect immediately

Contain urgent patient-safety, infection, supply, access or continuity risks before longer reform.

Redesign service

Join people, workflow, infrastructure, supplies, digital support and accountability around the user journey.

Pilot safely

Exercise a district detect-test-alert-respond pathway for one priority syndrome, including community communication.

Independent review

Compare benefit, harm, equity, cost, workforce burden and maintainability before expansion.

Decision checks

Clinical safety; Access; Consent; Privacy; Equity; Workforce; Affordability; Maintenance; Evidence

Section 05

Roadmap

Protect now, pilot carefully and build durable capability.

  • 0–90 DAYS
  • Diagnose & protect

Verify the pathway, immediate risk, accountable owner, minimum safe standard and urgent correction.

  • 3–18 MONTHS
  • Pilot & measure

Exercise a district detect-test-alert-respond pathway for one priority syndrome, including community communication.

  • 1–5+ YEARS
  • Institutionalise

Fund workforce, operations, maintenance, interoperability, supervision, public correction, independent evaluation and continuous learning.

Section 06

How to measure improvement

Track health benefit, safety, equity and durability—not activity alone.

KPI 01

Timeliness and completeness of surveillance

Record the definition, baseline, target, actual result, source, reporting period, affected group and uncertainty.

KPI 02

Vaccination coverage and equity

KPI 03

Alert-to-investigation time

KPI 04

Lab turnaround

KPI 05

Outbreak control time

Result status: Planned, baseline pending, active measurement, insufficient evidence, improved, mixed, no improvement or harmful. Never label a programme successful from spending, training, installation or coverage alone.

Section 07

Risks and protections

Improvement must not create avoidable clinical or social harm.

Clinical risk

Unsafe standardisation, delay, false reassurance or inappropriate escalation.

Equity risk

Remote, poor, disabled, female, older or language-minority users excluded.

Data risk

Consent failure, exposure, cyber harm, misidentification or bad-quality records.

Workforce risk

Automation or targets increase unsafe workload and conceal skill gaps.

Governance risk

Responsibility, funding, maintenance or remedy remains unclear.

15 questions, answered clearly

Questions about Immunisation & Infectious Disease Control

What does Immunisation & Infectious Disease Control focus on?

Delayed signals, incomplete testing and uneven vaccination can allow preventable transmission before action begins.

What changes does the page propose?

Measure the actual local failure in immunisation & infectious disease control, including distribution and missing evidence. Contain urgent patient-safety, infection, supply, access or continuity risks before longer reform. Join people, workflow, infrastructure, supplies, digital support and accountability around the user journey. Exercise a district detect-test-alert-respond pathway for one priority syndrome, including community communication.

Which parts need to work together?

The proposed system connects Vaccination and cold chain; Disease surveillance; Laboratory confirmation; Vector control; Infection prevention; Rapid-response teams; Antimicrobial resistance. Assign a responsible team, service standard, handoff and maintenance plan for each part

What local information is needed before taking action?

Record state, district, city/block, village/ward or facility; date and time; population or patient group without unnecessary identity; service stage; observed harm or delay; source/method; and uncertainty. For emergencies and personal treatment, contact qualified local services rather than waiting for platform review.

What could be causing the problem?

Possible causes to investigate include Need & access; Capacity & capability; Flow & coordination; Quality & safety; Finance & governance; Context & equity. Treat these as questions to test against local records and experience, rather than confirmed causes in every location.

What evidence should researchers collect?

Record the starting conditions, service records, affected users’ experience, costs and the source and date of each observation. Compare more than one explanation and state what is still uncertain. Use this evidence to assess Immunisation & Infectious Disease Control.

What could a first trial of Immunisation & Infectious Disease Control look like?

Exercise a district detect-test-alert-respond pathway for one priority syndrome, including community communication. Agree the place, responsible team, comparison, safety checks and measurement period before starting. The trial described here is a proposal, not a reported result.

How should improvement be measured?

The page proposes tracking Timeliness and completeness of surveillance; Vaccination coverage and equity; Alert-to-investigation time; Lab turnaround; Outbreak control time. Define each measure, record the starting value and reporting period, then compare later results using the same method. Report who benefits and any harm or uncertainty.

What risks and safeguards need attention?

The page flags Clinical risk; Equity risk; Data risk; Workforce risk; Governance risk. Unsafe standardisation, delay, false reassurance or inappropriate escalation. Remote, poor, disabled, female, older or language-minority users excluded. Consent failure, exposure, cyber harm, misidentification or bad-quality records. Automation or targets increase unsafe workload and conceal skill gaps. Responsibility, funding, maintenance or remedy remains unclear.

What is the suggested order of work?

Protect now, pilot carefully and build durable capability. 0–90 DAYS. Diagnose & protect. Verify the pathway, immediate risk, accountable owner, minimum safe standard and urgent correction. 3–18 MONTHS. Pilot & measure. Exercise a district detect-test-alert-respond pathway for one priority syndrome, including community communication. 1–5+ YEARS. Build lasting services. Fund workforce, operations, maintenance, systems working together, supervision, public correction, independent evaluation and continuous learning. These stages are planning ranges. Actual timing depends on local conditions, resources, permissions and delivery capacity.

Who should take responsibility for delivery?

Information Required: the named organisation and accountable local team. Responsibilities must cover Vaccination and cold chain; Disease surveillance; Laboratory confirmation; Vector control; Infection prevention; Rapid-response teams; Antimicrobial resistance. Assign an owner for each handoff, record how problems will be escalated, and agree who will fund and maintain the work.

What costs should be checked before approval?

This is a proposed pilot, not a completed project. The responsible team, location, budget, starting measurement and independent review must be agreed before implementation. Detect outbreaks early and protect people through vaccination and rapid response. This topic requires evidence of actual access, readiness, quality, safety, affordability and continuity—not only a scheme, facility or installed asset. Information Required: a local cost estimate, funding source and ongoing operating and maintenance budget. Include costs shifted to households or other services when comparing options.

How should access and fairness be checked?

Who needs care, who reaches it and who is excluded? Test records, direct observation, staff and patient experience, and credible alternatives before calling it a verified cause. How do geography, gender, disability, income, language and season change the pathway? Compare access, costs, safety and results across the groups affected in this location. Record missing information and correct exclusion before expanding the proposal.

When should the approach expand, change or stop?

Use the proposed measures — Timeliness and completeness of surveillance; Vaccination coverage and equity; Alert-to-investigation time — to review benefit, harm, cost and the ability to keep the service working. Expand only when the evidence supports it; change a partly effective design and stop an unsafe or ineffective approach.

Does this page establish that the proposal has succeeded?

No verified local result should be inferred from the proposal alone. Information Required: a dated starting measurement, later results, costs, affected groups and an independent assessment. The proposed review should examine Timeliness and completeness of surveillance; Vaccination coverage and equity; Alert-to-investigation time.